Tran, Oth
Silverman, Stuart
Xu, Xiaoqing
Bonafede, Machaon
Fox, Kathleen
McDermott, Michele
Gandra, Shravanthi
Funding for this research was provided by:
Amgen
Article History
Received: 23 September 2020
Accepted: 30 November 2020
First Online: 7 January 2021
Change Date: 29 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00198-022-06410-1
Compliance with ethical standards
:
: Xiaoqing Xu, Shravanthi Gandra, and Michele McDermott are employed by Amgen Inc. Oth Tran is employed by IBM Watson Health, which received funding from Amgen Inc. to conduct this study. Stuart Silverman is a consultant of Amgen Inc. Machaon Bonafede was employed by IBM Watson when the study was conducted, and is currently employed by Veradigm. Kathleen Fox is a consultant of Amgen, Inc..
: The codes that support the findings of this study are available from IBM Watson Health. Restrictions apply to the availability of these codes, which were used under license for this study.